Qutenza 179 mg cutaneous patch
Sponsors
Centre Hospitalier Regional Et Universitaire De Brest, University Hospital Of Clermont-Ferrand, Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Averitas Pharma Inc., Oncopole Claudius Regaud, Oncopole Claudius Regaud
Conditions
Chronic postchirurgical or post-traumatic neuropathic painHead and neck cancerPainful diabetic peripheral neuropathyPost-surgical neuropathic painPostmastectomy Syndromedigital osteoarthritis
Phase 2
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae Neuropathic Pain.
CompletedCTIS2024-515510-41-00
Start: 2021-04-28End: 2025-04-28Target: 130Updated: 2024-08-13
A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic symptoms, nerve fibers, and microcirculation in painful diabetic peripheral neuropathy
Not yet recruitingCTIS2025-523597-17-00
Target: 40Updated: 2026-01-20
Phase 3
Analgesic effectiveness of capsaicin 8% cutaneous patch for the treatment of chronic postsurgical or post-traumatic neuropathic pain: a randomized placebo controlled study in children aged 12 to 17-y
RecruitingCTIS2022-500265-27-00
Start: 2024-03-05Target: 46Updated: 2025-02-24
An interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial evaluating the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain
CompletedCTIS2024-514934-19-00
Start: 2021-11-08End: 2025-08-28Target: 204Updated: 2024-09-22
Phase 4
Capsaicin in digital osteoarthritis versus control : a randomized study
RecruitingCTIS2024-511159-16-00
Start: 2025-02-14Target: 120Updated: 2024-05-23
Prospective, randomized, blinded, comparative study between botulinum toxin and topical capsaicin in the treatment of postmastectomy syndrome. Pilot study
Not yet recruitingCTIS2024-513609-29-01
Target: 30Updated: 2024-09-04